Moodie J E, Moir D D
Br J Anaesth. 1976 Jun;48(6):571-4. doi: 10.1093/bja/48.6.571.
Blood loss and the incidence of emetic sequelae were assessed in 148 patients undergoing midcavity forceps delivery under continuous lumbar extradural analgesia. Five units of oxytocin i.v. was found to be as effective as ergometrine 0.5 mg i.v. in reducing blood loss at delivery. Nausea, retching or vomiting occurred in 35 (46%) of the mothers who received ergometrine and in none of those who received i.v. oxytocin. The cardiovascular side-effects of ergometrine and oxytocin are reviewed and compared with special reference to patients with hypertension and heart disease. It is suggested that 5 units of oxytocin i.v. should be preferred in these high-risk patients. Because of the absence of an emetic action, i.v. oxytocin is preferable to i.v. ergometrine for patients receiving extradural analgesia.
对148例在持续腰段硬膜外镇痛下行中位产钳分娩的患者评估了失血量和呕吐后遗症的发生率。发现静脉注射5单位缩宫素在减少分娩时的失血量方面与静脉注射0.5毫克麦角新碱效果相同。接受麦角新碱的母亲中有35例(46%)出现恶心、干呕或呕吐,而接受静脉注射缩宫素的母亲中无一例出现这些症状。对麦角新碱和缩宫素的心血管副作用进行了综述,并特别参照高血压和心脏病患者进行了比较。建议在这些高危患者中优先选择静脉注射5单位缩宫素。由于没有催吐作用,对于接受硬膜外镇痛的患者,静脉注射缩宫素比静脉注射麦角新碱更可取。